Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $100.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 211.72% from the stock’s current price. HC Wainwright also issued estimates for Immunocore’s FY2029 earnings at $7.53 EPS.
IMCR has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price target on shares of Immunocore in a report on Friday, January 10th. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $72.00 to $38.00 in a report on Monday, November 11th. UBS Group assumed coverage on Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $65.64.
View Our Latest Stock Report on Immunocore
Immunocore Stock Down 0.6 %
Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.59) earnings per share. Equities analysts expect that Immunocore will post -0.94 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Immunocore
Hedge funds and other institutional investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC raised its position in Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares during the period. Connective Portfolio Management LLC purchased a new stake in shares of Immunocore during the 3rd quarter valued at about $218,000. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after acquiring an additional 3,053 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Immunocore in the 3rd quarter worth approximately $406,000. Finally, Alpha DNA Investment Management LLC acquired a new stake in Immunocore in the third quarter valued at approximately $411,000. Institutional investors and hedge funds own 84.50% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Read More
- Five stocks we like better than Immunocore
- 3 Healthcare Dividend Stocks to Buy
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How Can Investors Benefit From After-Hours Trading
- What Does the Future Hold for Eli Lilly?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.